Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …

Lung cancer is the most frequent cancer with an aggressive clinical course and high
mortality rates. Most cases are diagnosed at advanced stages when treatment options are …

Lung cancer represents the leading cause of cancer-related deaths worldwide. Despite
great advances in its management with the recent emergence of molecular targeted …

Lung cancer is the leading cause of cancer mortality worldwide. Comprehensive genomic
profiling of lung cancers revealed their genetic heterogeneity and complexity and identified …

The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR)
mutated or EML4–ALK rearrangement-positive tumors are sensitive to tyrosine kinase …

Despite advances in surgery, chemotherapy, and radiotherapy over the last decades, the
death rate from lung cancer has remained largely unchanged, which is mainly due to …

While the development of EGFR-targeted tyrosine kinase inhibitors (TKIs) has revolutionized
treatment of EGFR mutation-positive non-small-cell lung cancer, acquired resistance to …

Of the numerous oncogenes implicated in human cancer, the most common and perhaps
the most elusive to target pharmacologically is RAS. Since the discovery of RAS in the …

The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been
major threats to people's health. With the identification of carcinogenic drivers in non-small …